GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (STU:ASZ1) » Definitions » Research & Development

Alimera Sciences (STU:ASZ1) Research & Development : €15.54 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Alimera Sciences Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Alimera Sciences's Research & Development for the three months ended in Mar. 2024 was €4.01 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €15.54 Mil.

Alimera Sciences Research & Development Historical Data

The historical data trend for Alimera Sciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences Research & Development Chart

Alimera Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.89 7.95 12.19 15.32 15.25

Alimera Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.89 3.37 3.79 4.37 4.01

Alimera Sciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €15.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alimera Sciences  (STU:ASZ1) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Alimera Sciences Research & Development Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Alimera Sciences (STU:ASZ1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (STU:ASZ1) » Definitions » Research & Development
Comparable Companies
ZOM LFCR TKNO OPTN ELTP RGC AQST EBS ESPR ETON ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 XSWX:SDZ VTRS NBIX
Traded in Other Exchanges
ALIM:USA ASZ1:Germany
Address
6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005
Website
https://www.alimerasciences.com
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Alimera Sciences (STU:ASZ1) Headlines

No Headlines